ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of De Novo Belatacept-Based Immunosuppression in Recipients of Kidneys at High Risk for Delayed Graft Function in the Setting of Lymphocyte Depleting Immune Modulation

T. L. Shertel1, M. A. Wynd1, M. A. Pereiras1, J. T. McKeen1, Y. Y. Yushkov2, B. R. Schleich3, S. E. Geatrakas2, A. Patel2, M. J. Goldstein2

1Pharmacy, Hackensack University Medical Center, Hackensack, NJ, 2Organ Transplant, Hackensack University Medical Center, Hackensack, NJ, 3Patient Safety and Quality, Hackensack University Medical Center, Hackensack, NJ

Meeting: 2020 American Transplant Congress

Abstract number: B-110

Keywords: Co-stimulation, Immunosuppression, Kidney transplantation, Renal function

Session Information

Session Name: Poster Session B: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Our center created an immunosuppression protocol using de novo belatacept (DNB) in the setting of lymphocyte depletion to increase the utilization of deceased donor kidneys at higher risk for delayed graft function (DGF) that would have been declined previously. The protocol was designed to reduce the nephrotoxic effects of calcineurin inhibitor (CNI)-based immunosuppression on the donor kidney with advanced donor or preservation-related injury. The experience of implementing this new protocol, potential side effects, and the early transplant results are described.

*Methods: A retrospective, observational study was performed on first time kidney transplant recipients treated with the DNB protocol from 10/1/2018 to 9/30/2019 (N=36). DNB protocol is defined as belatacept initiated within 7 days after transplant in patients receiving anti-thymocyte globulin induction therapy without concomitant CNIs.

Only adult patients who were EBV seropositive and received a deceased donor kidney at increased risk of DGF were included. Increased risk of DGF was defined as meeting one of the following criteria; anticipated cold ischemia time greater than 18 hours in cold static storage, donation after cardiac death, and donor-derived Stage 2 or 3 acute kidney injury.

*Results: The first 3-month follow-up for DGF, 30-day readmission, infections, adverse events and eGFR of the cohort are listed in Table 1. No patient had an acute rejection episode within 90 days of transplant. One patient died five weeks after transplant of a cardiac event with a functioning graft.

Table 1: DNB Performance and Adverse Event Summary
DGF 30 day Readmission Median eGFR at 90 days Leukopenia within 90 days UTI within 90 days BKV within 90 days CMV within 90 days Patient and Graft Survival
13/36 (36.11%) 11/36 (30.55%) 50.68 5/36 (13.89%) 5/36 (13.89%) 7/36 (19.44%) 1/36 (2.77%) 35/36 (97.22%)

*Conclusions: Three month outcomes with the DNB protocol are encouraging. Using DNB and avoiding CNIs is likely to promote utilization of kidneys at risk of DGF or being discarded. Longer term follow-up is necessary to assess further outcomes of the DNB protocol.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Shertel TL, Wynd MA, Pereiras MA, McKeen JT, Yushkov YY, Schleich BR, Geatrakas SE, Patel A, Goldstein MJ. Outcomes of De Novo Belatacept-Based Immunosuppression in Recipients of Kidneys at High Risk for Delayed Graft Function in the Setting of Lymphocyte Depleting Immune Modulation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-de-novo-belatacept-based-immunosuppression-in-recipients-of-kidneys-at-high-risk-for-delayed-graft-function-in-the-setting-of-lymphocyte-depleting-immune-modulation/. Accessed June 6, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences